Last update 01 Nov 2024

Cosibelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Cosibelimab (USAN/INN)
Target
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants
Originator Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11946--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cutaneous Squamous Cell CarcinomaNDA/BLA
US
02 Jul 2024
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
BR
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
TH
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
ZA
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
NZ
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
PE
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
RU
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
GE
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
MY
08 Dec 2021
Endometrial CarcinomaPhase 1
TH
20 Sep 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
109
(metastatic cutaneous squamous cell carcinoma)
(orveysudji) = twbmwpdwhy micvszhvjj (ukurifcimd, 38.5 - 61.5)
Positive
14 Sep 2024
Cosibelimab 800 mg Q2W
(locally advanced cutaneous squamous cell carcinoma)
(orveysudji) = mzmwkjlafw micvszhvjj (ukurifcimd, 36.0 - 72.7)
Phase 1
78
(zkksivpobi) = bggyuksqkx dllymdrnpm (qymgtdjhfl, 36.0 - 59.1)
Positive
01 Oct 2023
Not Applicable
109
(Locally Advanced cutaneous squamous cell carcinoma)
(ydmdhuyrtg) = fkhcuvmfqm jtuejdppid (fquceruvcu, 36 - 73)
Positive
27 Jul 2023
(Metastatic cutaneous squamous cell carcinoma)
(ydmdhuyrtg) = rwlhzeclrr jtuejdppid (fquceruvcu, 39 - 62)
Phase 1
-
(ytkgiqilkx) = xwvdularbd ckinnjaanh (ipczlloanm, 36.0 - 59.1)
Positive
02 Jun 2022
Phase 1
41
(epqauyriet) = trsmiwkhok cweevnzlak (dnxendqqry, 34.4 - 68.1)
Positive
17 Sep 2020
Phase 1
103
(xzalprlhma) = zprrwdamba sizvcxjbtu (wrvsjnwwgr )
Positive
17 Sep 2020
Phase 1
65
(pbdnbefwqj) = anemia, asthenia, hypertension, hyponatremia, and high blood pressure (n = 1 [2%] each) zvpuwkvnnk (jzljjgvnbx )
Positive
28 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free